The Combination of GS-441524 (Remdesivir) and Ribavirin Results in a Potent Antiviral Effect Against Human Parainfluenza Virus 3 Infection in Human Airway Epithelial Cell Cultures and in a Mouse Infection Model
Viruses · 26.01.2025 · 17 (2) · 172
DOI: 10.3390/v17020172 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 26.01.2025. Verfasst von Yuxia Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Virology, Antiviral Drug & Vaccine Researc…. Hauptthemen laut MEDLINE: Ribavirin, Antiviral Agents, Parainfluenza Virus 3, Human, Epithelial Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EU PANVIPREP, EU DURABLE, the China Scholarship Council.
Abstract (Originalsprache)
Human parainfluenza virus type 3 (HPIV-3) can cause severe respiratory diseases, particularly in young children, the elderly and immunocompromised. There are no approved antiviral drugs against this virus. We report that the combination of ribavirin with either remdesivir or its parent nucleoside GS-441524 results in a pronounced antiviral effect against HPIV-3 in LLC-MK2 cells and in human airway epithelial cells grown at the air–liquid interface. In AG129 mice intranasally inoculated with HPIV-3, the combined treatment with ribavirin and GS-441524 decreased infectious viral lung titers by >2.5 log10 to undetectable levels in 4 out of 11 mice and by 1.6 log10 in the remaining 7 mice as compared with the vehicle. The lungs of all mice that received the combined treatment appeared histologically normal or virtually normal, whereas 8 of 11 vehicle-treated mice presented with bronchopneumonia. By contrast, ribavirin alone did not result in a reduction in infectious viral lung titers; GS-441524 alone reduced infectious viral lung titers by 1.2 log10. Moreover, several mice in the single-treatment groups exhibited severe lung pathology. These findings may warrant exploring this combination in patients with severe HPIV-3 infections and possibly also against infections with other viruses that are susceptible in vitro to these two drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Virology, Antiviral Drug & Vaccine Research Group, B-3000 Leuven, Belgium.
- KU Leuven Department of Imaging and Pathology, Division of Translational Cell and Tissue Research, B-3000 Leuven, Belgium.
- VirusBank Platform, KU Leuven, B-3000 Leuven, Belgium.
ORCID-Profile: Yuxia Lin, Manon Laporte, Dirk Jochmans, Johan Neyts
Förderung
- EU PANVIPREP
- EU DURABLE
- the China Scholarship Council
- China Scholarship Council
Zitieren
APA
Lin, Y., Weynand, B., Zhang, X., Laporte, M., Jochmans, D., & Neyts, J. (2025). The Combination of GS-441524 (Remdesivir) and Ribavirin Results in a Potent Antiviral Effect Against Human Parainfluenza Virus 3 Infection in Human Airway Epithelial Cell Cultures and in a Mouse Infection Model. Viruses, 17(2), 172. https://doi.org/10.3390/v17020172
Vancouver
Lin Y, Weynand B, Zhang X, Laporte M, Jochmans D, Neyts J. The Combination of GS-441524 (Remdesivir) and Ribavirin Results in a Potent Antiviral Effect Against Human Parainfluenza Virus 3 Infection in Human Airway Epithelial Cell Cultures and in a Mouse Infection Model. Viruses. 2025;17(2):172. doi:10.3390/v17020172
BibTeX
@article{Lin2025,
author = {Lin, Yuxia and Weynand, Birgit and Zhang, Xin and Laporte, Manon and Jochmans, Dirk and Neyts, Johan},
title = {The Combination of GS-441524 (Remdesivir) and Ribavirin Results in a Potent Antiviral Effect Against Human Parainfluenza Virus 3 Infection in Human Airway Epithelial Cell Cultures and in a Mouse Infection Model},
journal = {Viruses},
year = {2025},
volume = {17},
number = {2},
pages = {172},
doi = {10.3390/v17020172}
}
EUVIMED